Do not start any new course of ulipristal for fibroids, MHRA advises

New temporary safety measures have been introduced for Esmya (ulipristal acetate) following reports of serious liver injury in women using the medicine to treat uterine fibroids.

by Chloe Harman
Esmya is licensed for intermittent or pre-operative treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age. | SOVEREIGN, ISM/SCIENCE PHOTO LIBRARY
Esmya is licensed for intermittent or pre-operative treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age. | SOVEREIGN, ISM/SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package